BioCentury | Sep 22, 2014

Weighing in on obesity

Contrave naltrexone/bupropion will be the first new obesity drug launched in the past two years to have the full weight of a large pharma partner with an established commercial footprint in the cardiometabolic space behind...
BC Week In Review | Mar 25, 2013
Clinical News

Empatic regulatory update

Orexigen disclosed in its 4Q12 earnings that FDA said Phase III data for obesity candidate Empatic may be sufficient to support an NDA submission without data from a cardiovascular outcomes trial. According to the company,...
BioCentury | Apr 2, 2012

Thinking small again

Buysiders shied away from small and micro-cap stocks over the last few years as poor performance and inadequate financing plagued these groups. But many investors now see them as undervalued. These include winners from last...
BC Week In Review | Jun 6, 2011
Clinical News

Contrave regulatory update

Orexigen suspended all of its obesity programs in the U.S. while it appeals FDA's request for a larger-than-expected cardiovascular outcomes trial prior to approval of Contrave. FDA's Division of Metabolic and Endocrinologic Products made the...
BioCentury | Jun 6, 2011

Obesity double standard

A recommendation by FDA that Orexigen Therapeutics Inc. demonstrate essentially zero cardiovascular risk for its obesity candidate Contrave naltrexone/bupropion signals that the agency is treating obesity very differently than diabetes, with the result that obesity...
BC Extra | Jun 3, 2011
Top Story

Orexigen falls on Contrave update

Orexigen Therapeutics Inc. (NASDAQ:OREX) lost $1.06 (33%) to $2.12 on Friday after suspending all of its obesity programs in the U.S. following FDA's request for a larger-than-expected cardiovascular outcomes trial prior to approval of Contrave...
BioCentury | Feb 7, 2011
Product Development

Obesity Reset

Even after FDA rejected the advice of its advisory committee and requested a cardiovascular outcomes trial of Orexigen Inc. 's Contrave bupropion/naltrexone to treat obesity, companies with earlier stage programs remain hopeful they will be...
BioCentury | Sep 6, 2010

A fatter deal wasn't needed

Orexigen Therapeutics Inc. could have held out for more money by waiting to partner Contrave until after the obesity candidate's FDA panel review on Dec. 7. But the biotech's decision to tie up with Takeda...
BC Week In Review | Oct 12, 2009
Clinical News

Empatic zonisamide SR/bupropion SR: Phase IIb data

In the double-blind, U.S. Phase IIb ZB-202 trial in 636 patients, both doses of Empatic met the primary endpoint of significantly increasing weight loss from baseline at 24 weeks vs. zonisamide alone, vs. bupropion alone...
BioCentury | Oct 5, 2009
Analyst Picks & Changes

Analysts Picks & Changes

Analysts Picks & Changes Company Bank Analyst Coverage Opinion Wk chg 10/2 cls Actelion Ltd. (SIX:ATLN) UBS Martin Wales Price target Sell -4% CHF 62.55 Wales raised his target to CHF57 from CHF54, noting strong...
Items per page:
1 - 10 of 38